Hormone receptor–positive (HR+, defined as positive estrogen receptor [ER] and/or positive progesterone receptor [PR] status) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer accounts for 65%–75% of all breast cancers, for which endocrine therapy is the standard of care (1). Here, ERBB2 is linked to breast carcinoma.